RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:98885

Bleeding diathesis due to glycoprotein VI deficiency

high confidenceSubtype of disorder

Publications

11

27th percentile

Trials

0

Interventional, condition-specific

Researchers

176

Distinct authors in sample

Gene link

GP6

Definitive

Readiness

3/6

Stages with a signal

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

BDPLT11 · GP6 inherited bleeding disorder, platelet-type · GP6-related platelet disorder · inherited bleeding disorder, platelet-type caused by mutation in GP6 · platelet-type bleeding disorder 11

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — GP6

  2. LiteraturePresent

    11 matched papers (9 in last 10 years) Source

  3. Phenotype characterisedPresent

    8 HPO annotations (e.g. Menorrhagia; Impaired ristocetin-induced platelet aggregation; Abnormal platelet count) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GP6).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

8

Associated phenotypes · MONDO:0013623

  • Menorrhagia
  • Impaired ristocetin-induced platelet aggregation
  • Abnormal platelet count
  • Impaired collagen-induced platelet aggregation
  • Epistaxis

Showing 5 of 8 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

11

11 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

11 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

9 in the last 10 years · high confidence · 27th percentile (publications denominator)

Phrase hits: 5 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

176

Distinct author names in 5 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bury L2 papers · 2024

    Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy;

    Papers in Europe PMC
  2. 02
    Cattaneo M2 papers · 2024

    Dipartimento di Scienze Della Salute, Università Degli Studi di Milano, Unità di Medicina, Azienda Ospedaliera San Paolo, Milan, Italy;

    Papers in Europe PMC
  3. 03
    Freson K2 papers · 2024

    Institute of Cancer Research, London, United Kingdom;

    Papers in Europe PMC
  4. 04
    Gresele P2 papers · 2024

    Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy;

    Papers in Europe PMC
  5. 05
    Lambert MP2 papers · 2024

    Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA;

    Papers in Europe PMC
  6. 06
    Megy K2 papers · 2024

    Department of Haematology, University of Cambridge, National Institute for Health Research BioResource-Rare Diseases, Cambridge University Hospitals, and.

    Papers in Europe PMC
  7. 07
    Akiki S1 paper · 2020

    Department of Laboratory Medicine & Pathology, Qatar Rehabilitation Institute, Hamad Bin Khalifa Medical City (HBKM), Doha, Qatar.

    Papers in Europe PMC
  8. 08
    Al Seraihi AFH1 paper · 2020

    Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

    Papers in Europe PMC
  9. 09
    Alessi MC1 paper · 2016

    Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine, Marseille, France;

    Papers in Europe PMC
  10. 10
    Alnajar J1 paper · 2020

    Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Bleeding diathesis due to glycoprotein VI deficiency — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Bleeding diathesis due to glycoprotein VI deficiency" OR "BDPLT11" OR "GP6 inherited bleeding disorder, platelet-type" OR "GP6-related platelet disorder" OR "inherited bleeding disorder, platelet-type caused by mutation in GP6" OR "platelet-type bleeding disorder 11") OR ("GP6 syndrome" OR "GP6-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Bleeding diathesis due to glycoprotein VI deficiency" OR "BDPLT11" OR "GP6 inherited bleeding disorder, platelet-type" OR "GP6-related platelet disorder" OR "inherited bleeding disorder, platelet-type caused by mutation in GP6" OR "platelet-type bleeding disorder 11"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:39:42.125Z